These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 9032105)
1. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Park IS; Kiyomoto H; Abboud SL; Abboud HE Diabetes; 1997 Mar; 46(3):473-80. PubMed ID: 9032105 [TBL] [Abstract][Full Text] [Related]
2. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Sharma K; Jin Y; Guo J; Ziyadeh FN Diabetes; 1996 Apr; 45(4):522-30. PubMed ID: 8603776 [TBL] [Abstract][Full Text] [Related]
3. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Gilbert RE; Cox A; Wu LL; Allen TJ; Hulthen UL; Jerums G; Cooper ME Diabetes; 1998 Mar; 47(3):414-22. PubMed ID: 9519748 [TBL] [Abstract][Full Text] [Related]
4. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Hill C; Flyvbjerg A; Grønbaek H; Petrik J; Hill DJ; Thomas CR; Sheppard MC; Logan A Endocrinology; 2000 Mar; 141(3):1196-208. PubMed ID: 10698197 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390 [TBL] [Abstract][Full Text] [Related]
6. [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats]. Liu BC; Luo DD; Sun J; Ma KL; Ruan XZ Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):320-3. PubMed ID: 12882713 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms through which bradykinin promotes glomerular injury in diabetes. Tan Y; Wang B; Keum JS; Jaffa AA Am J Physiol Renal Physiol; 2005 Mar; 288(3):F483-92. PubMed ID: 15692059 [TBL] [Abstract][Full Text] [Related]
8. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. Koya D; Jirousek MR; Lin YW; Ishii H; Kuboki K; King GL J Clin Invest; 1997 Jul; 100(1):115-26. PubMed ID: 9202063 [TBL] [Abstract][Full Text] [Related]
9. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Wang S; Denichilo M; Brubaker C; Hirschberg R Kidney Int; 2001 Jul; 60(1):96-105. PubMed ID: 11422741 [TBL] [Abstract][Full Text] [Related]
10. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Wang SN; Hirschberg R Am J Physiol Renal Physiol; 2000 Apr; 278(4):F554-60. PubMed ID: 10751215 [TBL] [Abstract][Full Text] [Related]
12. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. Kelly DJ; Gilbert RE; Cox AJ; Soulis T; Jerums G; Cooper ME J Am Soc Nephrol; 2001 Oct; 12(10):2098-2107. PubMed ID: 11562408 [TBL] [Abstract][Full Text] [Related]
13. Expression of cytoskeletal proteins during the course of experimental diabetic nephropathy. Sanai T; Sobka T; Johnson T; el-Essawy M; Muchaneta-Kubara EC; Ben Gharbia O; el Oldroyd S; Nahas AM Diabetologia; 2000 Jan; 43(1):91-100. PubMed ID: 10663221 [TBL] [Abstract][Full Text] [Related]
14. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Mizuno S; Nakamura T Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594 [TBL] [Abstract][Full Text] [Related]
15. Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment. Makino H; Mukoyama M; Sugawara A; Mori K; Suganami T; Yahata K; Fujinaga Y; Yokoi H; Tanaka I; Nakao K Clin Exp Nephrol; 2003 Mar; 7(1):33-40. PubMed ID: 14586741 [TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. Hill C; Flyvbjerg A; Rasch R; Bak M; Logan A J Endocrinol; 2001 Sep; 170(3):647-51. PubMed ID: 11524245 [TBL] [Abstract][Full Text] [Related]
17. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Al-Douahji M; Brugarolas J; Brown PA; Stehman-Breen CO; Alpers CE; Shankland SJ Kidney Int; 1999 Nov; 56(5):1691-9. PubMed ID: 10571777 [TBL] [Abstract][Full Text] [Related]
18. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946 [TBL] [Abstract][Full Text] [Related]
19. Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Gilbert RE; Wilkinson-Berka JL; Johnson DW; Cox A; Soulis T; Wu LL; Kelly DJ; Jerums G; Pollock CA; Cooper ME Kidney Int; 1998 Oct; 54(4):1052-62. PubMed ID: 9767521 [TBL] [Abstract][Full Text] [Related]
20. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]